ZURA BIO LIMITED Other Income and Expense
ZURA BIO LIMITED (ZURA) reported Other Income and Expense of $2.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-11
- ZURA BIO LIMITED nonoperating income (expense) for the quarter ending 2026-06-30 was $2.94M, a 41.90% increase year-over-year.
- ZURA BIO LIMITED nonoperating income (expense) for the quarter ending 2026-03-31 was $1.28M, a 29.58% decline year-over-year.
- ZURA BIO LIMITED nonoperating income (expense) for the quarter ending 2025-12-31 was $1.24M, a 41.34% decline year-over-year.
- ZURA BIO LIMITED nonoperating income (expense) for the quarter ending 2025-09-30 was $1.48M.
- ZURA BIO LIMITED nonoperating income (expense) for fiscal 2025 was $6.60M, a 136.76% increase from fiscal 2024.
- ZURA BIO LIMITED nonoperating income (expense) for fiscal 2024 was $2.79M, a 34.27% increase from fiscal 2023.
- ZURA BIO LIMITED nonoperating income (expense) for fiscal 2023 was $2.08M, a 66.66% decline from fiscal 2022.
- ZURA BIO LIMITED nonoperating income (expense) for fiscal 2022 was $6.22M.
| Period end | Nonoperating Income (Expense) 1 month | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 3 month as first filed | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 7 month | Nonoperating Income (Expense) 7 month as first filed | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 10 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.94M 10-Q · filed 2026-08-11 | $4.21M 10-Q · filed 2026-08-11 | $5.45M derived: sum of 3 quarters · filed 2026-08-11 | $6.93M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-07 | $2.51M derived: sum of 2 quarters · filed 2026-05-07 | $3.99M derived: sum of 3 quarters · filed 2026-05-07 | $6.06M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.71M derived: sum of 2 quarters · filed 2026-03-19 | $4.78M derived: sum of 3 quarters · filed 2026-08-11 | $6.60M 10-K · filed 2026-03-19 | |||||
| 2025-09-30 | $1.48M 10-Q · filed 2025-11-13 | $3.55M derived: sum of 2 quarters · filed 2026-08-11 | $5.36M 10-Q · filed 2025-11-13 | $7.47M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-06-30 | $2.07M 10-Q · filed 2026-08-11 | $3.88M 10-Q · filed 2026-08-11 | $5.99M derived: sum of 3 quarters · filed 2026-08-11 | $4.61M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-03-31 | $1.81M 10-Q · filed 2026-05-07 | $3.92M derived: sum of 2 quarters · filed 2026-05-07 | $2.54M derived: sum of 3 quarters · filed 2026-05-07 | $3.97M derived: sum of 4 quarters · filed 2026-05-07 | |||||
| 2024-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $724.00K derived: sum of 2 quarters · filed 2026-03-19 | $2.15M derived: sum of 3 quarters · filed 2026-03-19 | $2.79M 10-K · filed 2026-03-19 | |||||
| 2024-09-30 | -$1.38M 10-Q · filed 2025-11-13 | $47.00K derived: sum of 2 quarters · filed 2025-11-13 | $679.00K 10-Q · filed 2025-11-13 | $3.03M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $1.43M 10-Q · filed 2025-08-14 | $2.06M 10-Q · filed 2025-08-14 | $4.42M derived: sum of 3 quarters · filed 2025-08-14 | $6.33M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | $632.00K 10-Q · filed 2025-05-08 | $2.99M derived: sum of 2 quarters · filed 2025-05-08 | $4.90M derived: sum of 3 quarters · filed 2025-05-08 | $4.78M derived: sum of 4 quarters · filed 2025-05-08 | |||||
| 2023-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $4.27M derived: sum of 2 quarters · filed 2025-03-25 | $4.15M derived: sum of 3 quarters · filed 2025-03-25 | $2.08M 10-K · filed 2025-03-25 | |||||
| 2023-09-30 | $1.92M 10-Q · filed 2024-11-07 | $1.80M derived: sum of 2 quarters · filed 2024-11-07 | -$279.00K 10-Q · filed 2024-11-07 | $1.04M derived: sum of 4 quarters · filed 2024-11-07 | |||||
| 2023-06-30 | -$120.00K 10-Q · filed 2024-08-13 | -$2.20M 10-Q · filed 2024-08-13 | -$876.37K derived: sum of 3 quarters · filed 2024-08-13 | $125.70K derived: sum of 4 quarters · filed 2024-08-13 | |||||
| 2023-03-31 | -$2.08M 10-Q · filed 2024-05-09 | -$756.37K derived: sum of 2 quarters · filed 2024-05-09 | $245.70K derived: sum of 3 quarters · filed 2024-05-09 | $3.59M derived: sum of 4 quarters · filed 2024-05-09 | |||||
| 2022-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $2.32M derived: sum of 2 quarters · filed 2023-03-28 | $5.66M derived: sum of 3 quarters · filed 2023-03-28 | $6.22M 10-K · filed 2023-03-28 | |||||
| 2022-09-30 | $1.00M 10-Q · filed 2022-11-14 | $4.34M derived: sum of 2 quarters · filed 2022-11-14 | $4.90M 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | $3.34M 10-Q · filed 2022-08-12 | $3.90M 10-Q · filed 2022-08-12 | |||||||
| 2022-03-31 | $560.18K 10-Q · filed 2022-05-13 | ||||||||
| 2021-12-31 | $7.74M 10-K · filed 2023-03-28 | ||||||||
| 2021-09-30 | $6.11M 10-Q · filed 2022-11-14 | $6.41M 10-Q · filed 2021-11-19 | $6.11M 10-Q · filed 2022-11-14 | $6.41M 10-Q · filed 2021-11-19 | |||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |